MX2007010532A - Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. - Google Patents
Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.Info
- Publication number
- MX2007010532A MX2007010532A MX2007010532A MX2007010532A MX2007010532A MX 2007010532 A MX2007010532 A MX 2007010532A MX 2007010532 A MX2007010532 A MX 2007010532A MX 2007010532 A MX2007010532 A MX 2007010532A MX 2007010532 A MX2007010532 A MX 2007010532A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- type
- diabetes mellitus
- perdine
- sulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Se proporcionan en la presente compuestos de la formula (I) asi como sale farmaceuticamente aceptables de los mismos, en donde los sustituyentes son como aquellos descritos en la especificacion. Estos compuestos, y las composiciones farmaceuticas que los contienen, son utiles para el tratamiento de enfermedades tal como, por ejemplo, diabetes mellitus tipo II y sindrome metabolico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65827605P | 2005-03-03 | 2005-03-03 | |
PCT/EP2006/001603 WO2006094633A1 (en) | 2005-03-03 | 2006-02-22 | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007010532A true MX2007010532A (es) | 2007-10-12 |
Family
ID=36378808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007010532A MX2007010532A (es) | 2005-03-03 | 2006-02-22 | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060199816A1 (es) |
EP (1) | EP1866285A1 (es) |
JP (1) | JP2008531616A (es) |
KR (1) | KR100979577B1 (es) |
CN (1) | CN101133026B (es) |
AU (1) | AU2006222372B8 (es) |
BR (1) | BRPI0609062A2 (es) |
CA (1) | CA2598610C (es) |
IL (1) | IL185244A0 (es) |
MX (1) | MX2007010532A (es) |
WO (1) | WO2006094633A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
JP2008504274A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
BRPI0512535A (pt) * | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
JP2008504279A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
US20060122197A1 (en) * | 2004-08-10 | 2006-06-08 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
KR101368228B1 (ko) * | 2004-11-10 | 2014-02-27 | 인사이트 코포레이션 | 락탐 화합물 및 약제로서의 이의 용도 |
US8110581B2 (en) * | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
WO2006055752A2 (en) * | 2004-11-18 | 2006-05-26 | Incyte Corporation | INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME |
EP1931652A2 (en) * | 2005-09-21 | 2008-06-18 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
KR101415861B1 (ko) * | 2005-12-05 | 2014-07-04 | 인사이트 코포레이션 | 락탐 화합물 및 이를 사용하는 방법 |
US7998959B2 (en) * | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007089683A1 (en) * | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2007101270A1 (en) * | 2006-03-02 | 2007-09-07 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
US20070208001A1 (en) * | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
CA2649677A1 (en) * | 2006-05-01 | 2007-11-15 | Incyte Corporation | Tetrasubstituted ureas as modulators of 11-.beta. hydroxyl steroid dehydrogenase type 1 |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
CA2652375A1 (en) * | 2006-05-17 | 2007-11-29 | Incyte Corporation | Heterocyclic inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type i and methods of using the same |
US20090306048A1 (en) * | 2006-06-16 | 2009-12-10 | John Paul Kilburn | Pharmaceutical use of substituted piperidine carboxamides |
EP1918285A1 (en) | 2006-11-03 | 2008-05-07 | Merck Sante | Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors |
WO2008087654A2 (en) * | 2007-01-16 | 2008-07-24 | Cadila Healthcare Limited | PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
CA2711399C (en) | 2008-02-06 | 2016-10-11 | Banyu Pharmaceutical Co., Ltd. | 3-substituted sulfonylpiperidine derivative |
WO2009100994A1 (en) * | 2008-02-12 | 2009-08-20 | F. Hoffmann-La Roche Ag | Piperidine sulfonamide derivatives |
AU2009316802B2 (en) | 2008-11-21 | 2015-02-26 | Vtv Therapeutics Llc | Adamantyl benzamide compounds |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
US8258158B2 (en) * | 2009-09-11 | 2012-09-04 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
WO2013020440A1 (zh) * | 2011-08-09 | 2013-02-14 | 上海医药集团股份有限公司 | 酰胺衍生物、其制备方法、药物组合物和应用 |
US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
KR20210104730A (ko) * | 2018-12-18 | 2021-08-25 | 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 | 이소퀴놀린술포닐클로라이드 산부가염 및 그 제조 방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9604311D0 (en) * | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
DE19827640A1 (de) * | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
DE19962936A1 (de) * | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
AU2003269242A1 (en) * | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
US20060035884A1 (en) * | 2004-05-20 | 2006-02-16 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
BRPI0512535A (pt) * | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
JP2008504274A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
-
2006
- 2006-02-22 AU AU2006222372A patent/AU2006222372B8/en not_active Ceased
- 2006-02-22 KR KR1020077019963A patent/KR100979577B1/ko not_active IP Right Cessation
- 2006-02-22 CN CN2006800067895A patent/CN101133026B/zh not_active Expired - Fee Related
- 2006-02-22 BR BRPI0609062-1A patent/BRPI0609062A2/pt not_active IP Right Cessation
- 2006-02-22 JP JP2007557372A patent/JP2008531616A/ja active Pending
- 2006-02-22 WO PCT/EP2006/001603 patent/WO2006094633A1/en not_active Application Discontinuation
- 2006-02-22 EP EP06707167A patent/EP1866285A1/en not_active Withdrawn
- 2006-02-22 CA CA2598610A patent/CA2598610C/en not_active Expired - Fee Related
- 2006-02-22 MX MX2007010532A patent/MX2007010532A/es not_active Application Discontinuation
- 2006-03-01 US US11/365,053 patent/US20060199816A1/en not_active Abandoned
-
2007
- 2007-08-13 IL IL185244A patent/IL185244A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006222372A1 (en) | 2006-09-14 |
US20060199816A1 (en) | 2006-09-07 |
CA2598610A1 (en) | 2006-09-14 |
EP1866285A1 (en) | 2007-12-19 |
WO2006094633A1 (en) | 2006-09-14 |
KR20070099680A (ko) | 2007-10-09 |
CN101133026A (zh) | 2008-02-27 |
AU2006222372B2 (en) | 2009-11-19 |
AU2006222372B8 (en) | 2010-04-08 |
IL185244A0 (en) | 2008-02-09 |
KR100979577B1 (ko) | 2010-09-01 |
JP2008531616A (ja) | 2008-08-14 |
CA2598610C (en) | 2011-05-31 |
CN101133026B (zh) | 2011-07-06 |
BRPI0609062A2 (pt) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
TW200643013A (en) | Pyrazoles | |
WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
MX2009012285A (es) | Inhibidores de diacilglicerol aciltransferasa. | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
MX2008002062A (es) | Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
NO20054852L (no) | GFAT inhibitorer | |
TW200833675A (en) | Nicotinamide derivatives | |
NO20082496L (no) | Pyrazinderivater | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
TW200833663A (en) | Therapeutic agents | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2006077025A3 (en) | Morpholines as 5ht2c agonists | |
TW200639156A (en) | New compounds | |
MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
WO2007017728A3 (en) | Novel heterocyclic compounds | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |